Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Pre-Eclampsia, Obesity
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

In view of the known link between pre-eclampsia, overweight/obesity and chronic kidney disease, the aim is to offer for obese and overweight patients to reduce their BMI without reducing lean body mass. The POPADIPE project will make it possible to limit overweight or obesity by means of nutritional management chosen by the patient (hypocaloric or a dissociated diet). The latter has been the subject of little scientific investigation, particularly in relation to the management of post-pre-eclampsia.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Other: Hypocaloric diet — Hypocaloric diet
  • Other: Dissociated diet — Dissociated diet

Primary Outcomes

  • Demonstrate Efficiency of personalised dietary management on weight loss in patients with a history of pre-eclampsia (1 year after care)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-11-02
Completion: 2028-11-02
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Hospitalier le Mans
Contact Information
Study Contact:
Christelle JADEAU
+33244710781
cjadeau@ch-lemans.fr
Centre Hospitalier Du Mans
Françoise LIPPI
Centre Hospitalier Du Mans
Coralie BARDOU
Centre Hospitalier Du Mans
Interventions
  • Other: Hypocaloric diet — Hypocaloric diet
  • Other: Dissociated diet — Dissociated diet
Study Locations (1 sites)
Centre Hospitalier Du Mans, Le Mans, 72000 France
Eligibility Criteria
Inclusion Criteria: * Person affiliated to social security * Free, informed and written consent signed by the participant and the investigator (no later than the day of day of inclusion and before any examination required by the research) * Patient over 18 years of age at the time of inclusion and \< 45 years of age * Having had an pre-eclampsia in the last 5 years according to the definitions of the ISSHP 2018 * Patient with a BMI between 25 kg/m² and 40 kg/m² who accepts dietetic follow up * Patient with a medical prescription for dietetic follow-up aimed at losing weight loss * Patient with a balanced diet Exclusion Criteria: * Patients with a mental disability or language barrier that prevents them from understanding or consenting to the study * Patients deprived of their liberty by judicial or administrative decision * Patients under psychiatric care * Patients subject to a legal protection measure * Patients with cognitive disorders or defined eating disorders * Patients who are pregnant or breast-feeding * Patients undergoing steroid treatment and/or immunosuppression * Have been on a low-calorie or dissociated diet for at least 6 months * Patients with CKD stage ≥ 3A
Conditions Hepatocellular Carcinoma with PVTT
Phase PHASE2
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to evaluate the efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPS) plus half-dose donafenib (a kind of anti-angiogenesis agents) in advanced hepatocellular carcinoma (BCLC-C Stage) accompanied by tumor thrombosis-associated portal hypertension.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) — Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA
  • Drug: Donafenib — Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.

Primary Outcomes

  • Objective response rate (ORR) by RECIST 1.1 and mRECIST (From date of first dose of study drug until disease progression, stable disease, development of unacceptable toxicity, withdrawal of consent, or sponsor termination (up to 1 year))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-10-08
Completion: 2026-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fei Gao
Principal Investigators:
  • Fei Gao, M.D.,Ph.D. (PRINCIPAL_INVESTIGATOR) - Sun Yat-Sen University Cancer Center
Contact Information
Study Contact:
Fei Gao, M.D.,Ph.D.
+86-13760869828
gaof@sysucc.org.cn
Han Qi, M.D.
86-15920316143
qihan@sysucc.org.cn
Fei Gao, M.D.,Ph.D.
+86-13760869828
gaof@sysucc.org.cn
Sun Yat-sen University
Interventions
  • Procedure: Transjugular intrahepatic portosystemic shunt (TIPS) — Perform transjugular intrahepatic portosystemic shunt under the guidance of DSA
  • Drug: Donafenib — Half-dose donafenib, 100mg BID P.O. unless any evidence of disease progression or unacceptable side effects.
Study Locations (1 sites)
Sun Yat-sen University, Guangzhou, Guangdong 510060 China
Eligibility Criteria
Inclusion Criteria: 1. The patient voluntarily joined the study and signed an informed consent form; 2. ≥18 and ≤ 75 years old, both male and female; 3. Pathologically confirmed hepatocellular carcinoma, at least one measurable focus without local treatment (according to mRECIST or RECIST 1.1 requirements; 4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 5. BCLC-C stage accompanied by tumor thrombosis-associated portal hypertension; 6. Newly diagnosed patients who have not received local or systemic therapy in the past; 7. Expected survival period ≥ 3 months; 8. The functions of vital organs meet the following requirements (no blood components, cell growth factors and other corrective treatment drugs are allowed within 14 days before the first administration): the absolute count of neutrophils≥1.5×10\^9/L; Platelet ≥50×10\^9/L; Hemoglobin ≥60 g/L; Serum albumin ≥28 g/L; Thyroid-stimulating hormone (TSH)≤1×ULN (if abnormal, the levels of FT3 and FT4 should be examined at the same time, if the levels of FT3 and FT4 are normal, they can be included in the group); Bilirubin≤2×ULN (within 7 days before the first administration); ALT and AST ≤5×ULN (within 7 days before the first dose); Serum creatinine≤1.5×ULN; 9. Child-Pugh score ≤ 13 points; 10. Diagnosed with portal hypertension-related complications: Gastrointestinal bleeding; refractory or recurrent ascites; hepatic pleural effusion; portal vein tumor thrombus exceeds 50% of lumen area. 11. Non-surgical sterilization or female patients of childbearing age need to use a medically approved contraceptive method (such as an intrauterine device, contraceptive, or condom) during the study treatment period and within 3 months after the end of the study treatment period; Female patients of childbearing age who undergo surgical sterilization must be negative in serum or urine HCG within 72 hours before enrollment in the study; and must be non-lactating; for male patients whose partners are women of childbearing age, at the last time use effective methods for contraception within 3 months. Exclusion Criteria: 1. The patient has any active autoimmune disease or a history of autoimmune disease; 2. The patient is using immunosuppressive agents or systemic hormone therapy to achieve the purpose of immunosuppression (dose\>10mg/day prednisone or other curative hormones), and continues to use it within 2 weeks before enrollment; 3. Severe allergic reaction to any compositions of donafenib tablets or contrast media containing iodine ; 4. Central nervous system metastasis; 5. Patients who have received liver transplantation in the past; 6. Tumor thrombus beyond the portal vein range, such as hepatic vein, inferior vena cava, right atrium, splenic vein, superior mesenteric vein; 7. Suffer from high blood pressure and cannot be well controlled by anti-hypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); 8. Uncontrolled cardiac clinical symptoms or diseases, such as: NYHA level 2 or higher heart failure, unstable angina pectoris, myocardial infarction occurred within 1 year, clinically significant supraventricular or ventricular arrhythmia requires treatment or intervention , QTc\>450ms (male); QTc\>470ms (female); Abnormal coagulation function (INR\>2.0, PT\>16s), have bleeding tendency or are receiving thrombolysis or anticoagulation therapy, and allow the preventive use of low-dose aspirin and low molecular heparin; 9. Child-Pugh score \>13 points; 10. Arterial/venous thrombosis events that occurred within 6 months before randomization, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; 11. Known genetic or acquired bleeding and thrombotic tendency (such as hemophilia patients, coagulation dysfunction, thrombocytopenia, etc.); 12. Urine routine test showed urine protein ≥ ++ and confirmed 24-hour urine protein content\> 1.0 g; 13. The patient has active infection, fever of unknown origin within 7 days before medication ≥38.5℃, or baseline white blood cell count \>15×109/L; 14. Patients with congenital or acquired immune deficiencies (such as HIV-infected persons); 15. Moderate to severe pulmonary hypertension, pulmonary artery pressure was assessed by ultrasound \>40mmHg; 16. The patient suffered from other malignant tumors in the past 3 years or at the same time (except for cured skin basal cell carcinoma and cervical carcinoma in situ); 17. The patient has previously received other anti-PD-1 antibody therapy or other immunotherapy against PD-1/PD-L1, or has previously received apatinib therapy; 18. According to the judgment of the investigator, the patient has other factors that may affect the results of the study or cause the study to be terminated halfway, such as alcoholism, drug abuse, other serious diseases (including mental illness) that require combined treatment, and other abnormalities which may affect the efficacy and/or safety of patients.
Conditions Blood Pressure, Hypertension, Blood Pres...
Phase NA
Enrollment 50
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to evaluate the accuracy of the CART BP, a medically approved ring-type blood pressure monitor, in comparison to the traditional auscultatory method using a dual-head stethoscope. The comparison is conducted in accordance with the 2023 European Society of Hypertension (ESH) Recommendations, focusing on patients with suspected hypertension or hypotension. The evaluation includes accuracy measurements across various postures and during different exercise periods.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Device: CART BP — A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.
  • Device: sphygmomanometer — Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.

Primary Outcomes

  • Mean error and standard deviations of differences between CART BP and Reference (1 hour)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-22
Completion: 2025-08-15
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 50 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sky Labs
Collaborators: Samsung Medical Center
Principal Investigators:
  • Seung Woo Park (PRINCIPAL_INVESTIGATOR) - Samsung Medical Center
Contact Information
Study Contact:
Gerrard Kim
+82-10-5192-8767
gerrard.kim@skylabs.io
Yujung Kang
+82-10-9764-7432
yujung.kang@skylabs.io
Seung Woo Park
Samsung Medical Center
Interventions
  • Device: CART BP — A ring-type medical device worn by the subject that non-invasively measures systolic and diastolic blood pressure, as well as pulse rate.
  • Device: sphygmomanometer — Blood pressure measurement method utilizing a two-headed stethoscope, allowing two observers to simultaneously hear the Korotkoff sounds.
Study Locations (1 sites)
Samsung Medical Center, Seoul, South Korea
Eligibility Criteria
Inclusion Criteria: * Subjects aged 18 years or older but younger than 80 years * Individuals who voluntarily decide to participate in this clinical trial and provide written consent to the information and consent form * Individuals willing to comply with the clinical trial protocol Exclusion Criteria: * Subjects who do not consent to the study * Obese individuals with a Body Mass Index (BMI) of 30 or higher (concerns about measurement errors as the standard 24-hour ambulatory blood pressure monitor cuff may not fit the arm properly) * Patients or volunteers who are pregnant * Patients or volunteers with underlying heart diseases: those with a history of hospitalization for heart failure, valvular disease, or myocardial infarction * Patients or volunteers diagnosed with atrial fibrillation on a 12-lead electrocardiogram (ECG) within the past 6 months * Patients or volunteers with end-stage renal disease (undergoing dialysis) * Patients or volunteers unable to perform repeated exercises required for the study * Patients or volunteers with a systolic blood pressure (SBP) exceeding 160 millimeters of mercury (mmHg) * Patients or volunteers with a systolic blood pressure (SBP) exceeding 160 millimeters of mercury (mmHg) and/or a diastolic blood pressure (DBP) exceeding 100 millimeters of mercury (mmHg) (for exercise tests)
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Phase Not Applicable
Enrollment 14
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This is single-arm, observational, academic, investigator-driven study investigating the efficacy of liver transplantation after successful and sustained downstaging/tumor control of liver-limited unresectable intrahepatic cholangiocarcinoma. The downstaging protocol includes chemotherapy +/- immunotherapy and transarterial radioembolization (TARE) with Yttrium-90 in various combinations.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • 3-year overall survival vs unresectable patients (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-03-20
Completion: 2027-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 14 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Contact Information
Study Contact:
Vincenzo Mazzaferro, MD, PhD
0223902760
vincenzo.mazzaferro@istitutotumori.mi.it
Marianna Maspero, MD
0223904066
marianna.maspero@istitutotumori.mi.it
Fondazione IRCCS Istituto Nazionale Tumori di Milano
Vincenzo Mazzaferro, MD, PhD
Fondazione IRCCS Istituto Nazionale Tumori di Milano
Interventions
N/A
Study Locations (1 sites)
Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Milan 20133 Italy
Eligibility Criteria
Inclusion Criteria: * Histological diagnosis of iCCA (biopsy-proven tumor) * Either first diagnosis or post-resection recurrence (occurring ≥ 6 months after resection) * Unresectability assessment due to tumor location (leading to insufficient live remnant with/out implementation of hypertrophic parenchymal techniques) or underlying liver disease. Non-resectability assessed by an expert surgical team with experience on both resection and transplantation (centralized at INT Milan). * Age between 18 and 70 years * No macrovascular tumor invasion (NB: portal vein and/or hepatic vein occlusion from the external tumor compression and classified as "encasement" could be considered after expert radiology review) * No extrahepatic spread * Disease stability for at least 6 months * CA 19-9 \< 200 u/ml at transplant listing in absence of jaundice * No medical and surgical contraindications to liver transplantation * Good performance status, Eastern Cooperative Oncology Group (ECOG) 0 or 1 * No concomitant malignancies or history of other malignancies in the previous 5 years * Written informed consent Exclusion Criteria: * Hilar and distal cholangiocarcinoma * Progression of disease under chemotherapy +/- radiation therapy, assessed with either RECIST, mRECIST or Choi criteria * Evidence of lymph-nodal metastases * Evidence of extrahepatic disease * Prior extrahepatic metastatic disease * Concomitant malignancies or history of other malignancies in the previous 5 years * Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study or evaluation of the study results * Any reason why, in the opinion of the investigator, the patient should not participate to the study
Conditions Portal Hypertension Related to Cirrhosis...
Phase Not Applicable
Enrollment 450
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the role of spleen shear wave elastography (SWE-SSM) for ruling in and ruling out clinically significant portal hypertension (CSPH) in patients with compensated advanced chronic liver disease (cACLD) and for ruling in and ruling out high-risk esophageal varices (HRV) in patients with CSPH. Secondary objectives of the study include the investigation of the correlation between SWE-SSM and portal pressure in a subgroup of patients undergoing hepatic venous pressure gradient (HVPG) measurement and between SWE-SSM and transient elastography (TE-SSM). The values of SWE-SSM and SWE-LSM will be assessed during the ultrasound examination to which the patient will be subjected according to their care pathway. If inclusion criteria are met and informed consent is obtained, spleen elastography will be carried out (in addition to the routine SWE-LSM planned in clinical practice). Spleen elastography will not alter the standard ultrasound examination but represents a non-invasive diagnostic addition. There will be no treatment or experimental intervention that will modify the patient's condition or directly influence their clinical course. The aim is to collect data based on clinical observations without altering the treatment or the natural course of the disease.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • CSPH (2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-08-20
Completion: 2027-08-20
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 450 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Contact Information
Study Contact:
Matteo Garcovich doctor
0039 0630156018
matteo.garcovich@policlinicogemelli.it
Garcovich
0630155052
matteo.garcovich@policlinicogemelli.it
Ultrasound diagnostic and interventional service "Policlinico A.Gemelli"
Interventions
N/A
Study Locations (1 sites)
Ultrasound diagnostic and interventional service "Policlinico A.Gemelli", Roma, Italia 00168 Italy
Eligibility Criteria
Inclusion Criteria: * Age greater than 18 years; * SWE-LSM ≥9 kPa and/or TE-LSM ≥15 kPa; Exclusion Criteria: * Presence of transjugular intrahepatic porto-systemic shunt (TIPS);· * Surgical absence of the spleen; * Grade 3 ascites; * History of variceal bleeding; * Refusal to participate in the study.
Conditions Chronic Kidney Disease, Diabetes, Hypert...
Phase Not Applicable
Enrollment 2500
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Faced with limited access to preventative health care services, Indigenous people living in rural and remote communities are at a higher risk of Chronic Kidney Disease (CKD) and kidney failure, when compared to the general population. The goal of this project is to perform point-of-care testing for CKD and its risk factors, including diabetes and high blood pressure, for individuals residing in rural and remote Indigenous communities across the Canadian provinces of Manitoba, British Columbia, Alberta, Saskatchewan, and Ontario. In addition to providing individuals with information about their risk of developing CKD, as well as providing tailored treatment plans, this study will help provide evidence to develop a permanent CKD surveillance system in all Indigenous communities across Canada, consequently decreasing the burden of CKD and kidney failure in these communities.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Interventions / Regimen

  • Other: Point-of-care screening — After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a "closed loop" system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations.

Primary Outcomes

  • Biomarkers of Kidney Function (1 day (At time of screening))
  • Diabetes (1 day (At time of screening))
  • Elevated Blood Pressure (1 day (At time of screening))
  • Kidney Failure Risk (1 day (At time of screening))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2019-10-01
Completion: 2025-12
Eligibility
Age: 10 Years – 80 Years
Sex: ALL
Volunteers: true
Enrollment: 2500 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Manitoba
Collaborators: Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease, Alberta Health services, First Nations Health Authority, First Nations Health and Social Secretariat of Manitoba, Research Manitoba, Shared Health Laboratory Services of Manitoba, Seven Oaks Hospital Chronic Disease Innovation Centre, Keewatinohk Inniniw Minoayawin Inc. (KIM)
Principal Investigators:
  • Paul Komenda, MD MHA (PRINCIPAL_INVESTIGATOR) - University of Manitoba
Contact Information
Study Contact:
Maria James, MSc
2049513040
mjames4@sogh.mb.ca
Deenaz Zaidi, BSc
deenaz@ualberta.ca
Alberta Health Services
Catherine Turner
catherine.turner@fnha.ca
First Nations Research and Knowledge Exchange
Interventions
  • Other: Point-of-care screening — After consent is obtained, a registered nurse will administer a demographic questionnaire, collecting the participant's personal health number, age, gender, date of birth, and name of community. Physical data including height, weight, and blood pressure will also be collected. A blood sample and a urine sample will be taken, with point-of-care testing being performed during the screening appointment to allow for results of the testing to be received and discussed with each patient at the time of the appointment. After screening, to ensure a "closed loop" system of care, patients at the highest risk of kidney failure will be referred to a nephrologist, while those at lower risk will be referred to their primary care provider with specific treatment and re-testing recommendations.
Study Locations (3 sites)
Alberta Health Services, Calgary, Alberta T2W1S7 Canada
First Nations Research and Knowledge Exchange, West Vancouver, British Columbia V7T 1A2 Canada
Chronic Disease Innovation Centre, Winnipeg, Manitoba R2V 3M3 Canada
Eligibility Criteria
Inclusion Criteria: * All individuals aged 10 years old - 80 years old will be recruited for screening, regardless of known CKD risk factors, such as diabetes, elevated blood pressure, or family history of kidney disease. Exclusion Criteria: * None.
Conditions HER2 Negative Breast Cancer
Phase PHASE2
Enrollment 140
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This is a Phase II, two-arm, single center, patient preference study designed to evaluate the impact of omitting adjuvant chemotherapy in moderate to high-anatomical risk, low-genomic risk (men or premenopausal women T2-3N0 and RS 16-25, or T1-3N1-2 and RS ≤ 25, and postmenopausal women T2-3N0 and RS 26-30, or T1-3N1 and RS 26-30, or T1-3N2 and RS ≤ 25),

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Ribociclib 400mg — 400 mg (2 x 200 mg tablets by mouth) once daily on days 1 to 21 of a 28-day cycle, followed by seven days off ribociclib (Days 22 to 28).
  • Drug: Letrozole 2.5mg — Letrozole will be administered as an endocrine therapy. The regimen will differ depending on the demographic of the patient. For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously.
  • Drug: Anastrazole 1mg — For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously.
  • Drug: Goserelin 3.6 MG — For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously, concurrently with goserelin 3.6 mg monthly injection.
  • Radiation: Adjuvant chemotherapy — Adjuvant chemotherapy dose modifications in Arm 2 will be per institutional guidelines and investigator discretion.

Primary Outcomes

  • Discontinuation rate of ribociclib in patients with resected moderate to high-anatomical risk, low-genomic risk, ER-positive, HER2-negative breast cancer (Within one year of treatment)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-07-09
Completion: 2030-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 140 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Yale University
Collaborators: Novartis, Breast Cancer Research Foundation
Principal Investigators:
  • Jing Du (PRINCIPAL_INVESTIGATOR) - Yale University
Contact Information
Study Contact:
Stephanie Ladd
954-895-0576
stephanie.ladd@yale.edu
Carl Brown
203-785-4095
carl.brown@yale.edu
Yale University
Interventions
  • Drug: Ribociclib 400mg — 400 mg (2 x 200 mg tablets by mouth) once daily on days 1 to 21 of a 28-day cycle, followed by seven days off ribociclib (Days 22 to 28).
  • Drug: Letrozole 2.5mg — Letrozole will be administered as an endocrine therapy. The regimen will differ depending on the demographic of the patient. For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously.
  • Drug: Anastrazole 1mg — For postmenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously. For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously.
  • Drug: Goserelin 3.6 MG — For men or premenopausal women: Letrozole 2.5 mg by mouth daily continuously or anastrozole 1 mg by mouth daily continuously, concurrently with goserelin 3.6 mg monthly injection.
  • Radiation: Adjuvant chemotherapy — Adjuvant chemotherapy dose modifications in Arm 2 will be per institutional guidelines and investigator discretion.
Study Locations (1 sites)
Yale University, New Haven, Connecticut 06511 United States
Eligibility Criteria
Inclusion Criteria: 1. Female or male age ≥ 18 years old and have the ability to understand and the willingness to sign a written informed consent document. 2. Participants may have ipsilateral or contralateral synchronous breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. 3. Participants may have multicentric or multifocal breast cancer if the highest stage tumor meets entry criteria, and the other sites of disease would not require chemotherapy or HER2-directed therapy. 4. Participants underwent a total mastectomy, skin-sparing mastectomy, nipple-sparing mastectomy, or a lumpectomy. 5. Participants must have undergone axillary staging with sentinel node biopsy (SNB), targeted axillary dissection (TAD), or axillary lymph node dissection (ALND). 6. The following staging criteria must be met postoperatively according to AJCC 8th edition criteria: men or premenopausal women T2-3N0 and RS 16-25, or T1-3N1-2 and RS ≤ 25, and postmenopausal women T2-3N0 and RS 26-30, or T1-3N1 and RS 26-30, or T1-3N2 and RS ≤ 25. 7. The tumor must be ER-positive (≥ 10%), HER2-negative, by current ASCO/CAP guidelines based on testing results. HER2-negative breast cancer is defined as a negative in situ hybridization test or an immunohistochemistry (IHC) status of 0 or 1+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required to confirm the participant's HER2-negative status (based on the most recently analyzed tissue sample tested by a local laboratory). 8. Participants with known menopausal status at the time of screen. a. Postmenopausal status is defined as: i. Participant underwent bilateral oophorectomy, or ii. Age ≥ 60 years, or Age \< 60 years and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, toremifene or ovarian suppression) and Follicle-stimulating hormone (FSH) and plasma estradiol are in the postmenopausal ranges per local normal ranges. Note: All women who do not meet the criteria for postmenopausal status are considered premenopausal for the purpose of this trial. 9. HIV-infected participants with undetectable viral load within 6 months and in long term anti-retroviral therapy that would not have a significant drug-drug interaction with ribociclib are eligible for this trial. 10. Radiation therapy should be used according to standard guidelines. 11. Participants must have an ECOG performance status of 0 to 1 within 28 days prior to registration of the study. 12. Participant is able to swallow oral medications. 13. Participants must have adequate organ and marrow function as defined below. All laboratory values must be obtained within 28 days prior to registration of the study. 1. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L. 2. Platelets ≥ 100 × 109/L. 3. Hemoglobin ≥ 9.0 g/dL. 4. Estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73m2 according to the Modification of Diet in Renal Disease (MDRD) formula. 5. Alanine transaminase (ALT) \< 2.5 × Upper Limit Normal (ULN). 6. Aspartate transaminase (AST) \< 2.5 × ULN. 7. Total serum bilirubin \< ULN; or total bilirubin ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN in patients with well documented Gilbert's Syndrome. 8. Patient must have the following laboratory values within normal limits or corrected to within normal limits with supplements (the local laboratory value should be documented within normal limits after the correction) before enrollment: * Potassium. * Magnesium. * Total Calcium (corrected for serum albumin). 14. Standard 12-lead ECG values assessed as: QTcF interval (using Fridericia's correction) at screening \< 450 msec. Resting heart rate 50-90 beats per minute (determined from the ECG). 15. Participant must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other trial procedures. 16. Participants must adhere to the following reproductive and contraceptive requirements while on study treatment and within three months after receiving the last dose of the treatment drugs. a. General requirements: i. Participants must not be pregnant or breastfeeding. ii. Participants must not donate or freeze eggs for future use related to assisted reproduction during the course of this study or within three months after receiving the last dose of the treatment drugs. b. For participants of childbearing potential: i. A participant of childbearing potential is defined as an individual who is premenopausal and capable of becoming pregnant. This includes individuals using contraception, those who are sexually inactive, and those with partners who have undergone a vasectomy. A participant is considered of childbearing potential if they have reached menarche, have not yet met the criteria for postmenopause (defined as more than 12 consecutive months of amenorrhea without any other medical cause), and have not undergone surgical sterilization (such as hysterectomy or oophorectomy). ii. A negative highly sensitive serum pregnancy test (for β-hCG) must be obtained within two weeks of starting the treatment drug administration. iii. Participants must practice at least one highly effective method of contraception. c. Highly effective methods of contraception include, but are not limited to: i. Total abstinence (no sexual relations), when this is in line with your preferred and usual lifestyle. Periodic abstinence like calendar, ovulation, symptothermal, post-ovulation methods, and withdrawal are not acceptable methods of contraception. ii. Total hysterectomy (surgical removal of the uterus and cervix) or tubal ligation (getting your "tubes tied") at least six weeks before taking study treatment. iii. Your male partner has already been sterilized with the appropriate documentation. The sterilized male partner should be your sole partner. iv. Placement of an intrauterine device (IUD) v. The use of oral (estrogen and progesterone), injected or implanted hormonal methods of contraception or intrauterine system (IUS) or any other form of hormonal contraception (e.g., hormone vaginal ring, hormonal-based IUD or transdermal hormone contraception) is not allowed in this study. 17. Participant has no contraindication for the adjuvant ET in the trial and is planned to be treated with ET for five years or more. Exclusion Criteria: Participants who meet any of the following criteria will be excluded from study entry: 1. Definitive clinical or radiologic evidence of distant metastases of breast cancer beyond regional lymph nodes (stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative surgery. 2. T4 tumors, including inflammatory breast cancer. 3. N3 tumors. 4. Participants that have received neoadjuvant chemotherapy or biotherapy. 5. Participant is concurrently using hormone replacement therapy. 6. Participants with a known hypersensitivity to any of the excipients of ribociclib and/or ET (e.g. rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, glucose-galactose malabsorption, and soy allergy). 7. Participant has received any CDK4/6 inhibitor. 8. Participant has a concurrent invasive malignancy or a prior invasive malignancy that requires systemic therapy or place them at more than minimal risk of mortality in the next 5 years. 9. Participant has known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection (testing is not mandatory, unless required by local regulation). 10. Life expectancy of \<5 years due to co-morbid conditions in the opinion of the treating investigator. 11. Non-epithelial breast malignancies such as sarcoma or lymphoma. 12. Hormonally based contraceptive measures must be discontinued prior to registration (including progestin/progesterone IUDs). 13. Pregnancy or lactating women or women who plan to become pregnant or breast-feed during t
Conditions Breast Cancer, Triple Negative Breast Ca...
Phase PHASE2
Enrollment 369
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Triple-negative breast cancer (TNBC) is a special subtype of breast cancer that lacks the expression of ER, PR, and Her-2 proteins, accounting for 15%-20% of all breast cancers.TNBC patients do not benefit from endocrine therapy or HER-2-targeted therapy, but are sensitive to cytotoxic drug therapy.Although the survival of TNBC patients has improved significantly compared with the past, it is still the type with the worst prognosis among all subtypes of breast cancer. Methods and drugs to further improve the therapeutic effect of TNBC patients are still being explored. Camrelizumab, a PD-1 inhibitor produced by Hengrui, has been approved for the treatment of various malignant tumors including advanced lung cancer, advanced liver cancer and advanced esophageal cancer. Shows good therapeutic effect and safety. Therefore, this study intends to explore the superiority of camrelizumab on the basis of the less toxic anthracycline-free TCb regimen.In order to provide more effective and safe neoadjuvant therapy for lymph node-positive TNBC patients.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: (Carrelizumab + TCb) regimen — Carrelizumab +docetaxel + carboplatin regimen
  • Drug: TCb regimen — docetaxel + carboplatin regimen

Primary Outcomes

  • Pathological complete response rate (pCR rate) (up to 24 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2022-12-20
Completion: 2029-12-31
Eligibility
Age: 18 Years – 70 Years
Sex: FEMALE
Volunteers: false
Enrollment: 369 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Zhenzhen Liu
Principal Investigators:
  • Zhenzhen Liu (PRINCIPAL_INVESTIGATOR) - Study Principal Investigator
Contact Information
Study Contact:
Zhenzhen Liu
13603862755
liuzhenzhen73@126.com
Dechuang Jiao
13598004327
jiaodechuang@163.com
Zhen Liu
18603723729
Henan cancer hospital
Interventions
  • Drug: (Carrelizumab + TCb) regimen — Carrelizumab +docetaxel + carboplatin regimen
  • Drug: TCb regimen — docetaxel + carboplatin regimen
Study Locations (1 sites)
Henan cancer hospital, Zhengzhou, Henan China
Eligibility Criteria
Inclusion Criteria: 1. Age: 18-70 years old 2. cT2 - cT4d, or cT1c with axillary lymph node metastasis confirmed clinically and pathologically; 3. Pathologically proven triple negative breast cancer: Triple-negative breast cancer is defined as: * Negative for ER and PR (IHC nuclear staining \<10%) * Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with no amplification by FISH); 4. Has clinically measurable lesions:Measurable lesions on ultrasound, mammography, or MR (optional) within 1 month before randomization; 5. Organ and bone marrow function tests within 1 month before chemotherapy suggest no contraindications to chemotherapy; 6. Cardiac ultrasound EF value ≧55%; 7. Females of childbearing age, with a negative serum pregnancy test 14 days before randomization; 8. ECOG score≤1 point; 9. Sign informed consent; Exclusion Criteria: 1. The patient has evidence of metastatic breast cancer; 2. For this disease, chemotherapy, endocrine therapy, targeted therapy, radiation therapy, etc. have been received; 3. The patient has a second primary malignancy other than adequately treated skin cancer; 4. The patient has been treated with anti-programmed cell death protein 1 (anti-PD-1), anti-programmed death ligand 1 (anti-PD-L1) or anti-PD-L2 drugs, or other immunotherapy; 5. The patient has been diagnosed with immunodeficiency disease or autoimmune disease; 6. The patient has severe lung or heart disease; 7. The patient has active hepatitis B and C; 8. The patient has a history of organ transplantation or bone marrow transplantation; 9. pregnant or breastfeeding women; 10. The investigators considered chemotherapy contraindicated due to serious, uncontrolled other medical conditions.
Conditions Cancer of Breast, Trastuzumab Emtansine,...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • progression-free survival (PFS) (PFS is defined as the time from treatment initiation to the first occurrence of disease progression or death from any cause, whichever occurs first, assessed up to 12 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-02-26
Completion: 2029-09-30
Eligibility
Age: 19 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Seoul National University Hospital
Contact Information
Study Contact:
Kyung-Hun Lee, MD, PhD
82-2-2072-7207
kyunghunlee@snu.ac.kr
Kyung-Hun Lee, MD, PhD
82-2-2072-7207
kyunghunlee@snu.ac.kr
Seoul National University Hospital
Interventions
N/A
Study Locations (1 sites)
Seoul National University Hospital, Seoul, 03080 South Korea
Eligibility Criteria
Inclusion Criteria: * HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer * Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting * Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression Exclusion Criteria: * Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study) * Has been previously treated with T-DM1 for advanced breast cancer * Has been previously treated with 4 or more lines of therapy for advanced breast cancer * Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).
Conditions Breast Cancer, Liposomal Doxorubicin, Ef...
Phase Not Applicable
Enrollment 150
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study aims to observe and evaluate the efficacy and safety of a liposomal doxorubicin containing regimen in the postoperative adjuvant treatment of breast cancer patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Interventions / Regimen

  • Drug: Liposomal doxorubicin containing regimen — Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.

Primary Outcomes

  • Cardiac safety (10 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-05-01
Completion: 2032-10
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 150 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine
Contact Information
Study Contact:
Xiaochen Wang, Dr.
+86 13958161286
wangxiaochen@zju.edu.cn
Shizhen Zhang, Dr.
+86 15168338547
zhangshizhen@zju.edu.cn
Xiaochen Wang, Dr.
+86 13958161286
wangxiaochen@zju.edu.cn
Second Affiliate Hospital of Zhejiang University
Interventions
  • Drug: Liposomal doxorubicin containing regimen — Liposomal doxorubicin hydrochloride (PLD) 30-40mg/m2 D1 + other drugs (decided by investigators); All patients were treated with 4 cycles.
Study Locations (1 sites)
Second Affiliate Hospital of Zhejiang University, Hangzhou, Zhejiang 310009 China
Eligibility Criteria
Inclusion Criteria: 1. Female, aged 18-75 years; 2. Primary breast cancer diagnosed histopathologically; 3. Adjuvant chemotherapy regimens include liposomal doxorubicin; 4. ECoG PS score: 0-1 points; 5. Left ventricular ejection fraction (LVEF) ≥ 55%; 6. Estimated survival ≥ 6 months; 7. Major organ function is normal, i.e. meets the following criteria: ① And white blood cells ≥ 4.0 × 10 9 / L, neutrophil count (ANC) ≥ 1.5 × 10 9 /L;② Platelets ≥ 100 × 10 9 /L;③ And hemoglobin ≥ 10 g / dl; ④ Serum creatinine ≤ 1.5 × ⑤ the upper limit of normal (ULN) Mmol / L and aspartate transaminase (AST) ≤ 2.5 × ULN;⑥ Alanine transaminase (ALT) ≤ 2.5 × ULN;⑦ Total bilirubin ≤ 1.5 × ULN;⑧ Serum creatinine ≤ 1.5 × ULN; 8. Subjects voluntarily join this study, sign the informed consent form, have good compliance and cooperate with follow-up. Exclusion Criteria: 1. Pregnant, lactating patients; 2. Breast cancer has been found to have distant metastasis; 3. Those with peripheral nervous system disorders caused by the disease or with a history of significant mental disorders and central nervous system disorders; 4. Those with severe infection or active peptic ulcer requiring treatment; 5. Allergic to chemotherapy drugs; 6. Cancer free period less than 5 years except for cured basal cell carcinoma of the skin and cured carcinoma in situ of the cervix; 7. Severe liver disease (e.g., cirrhosis, etc.), renal disease, respiratory disease, or uncontrolled diabetes; 8. Patients who are participating in other clinical trials or within a month.
Conditions Lung Cancer, Breast Cancer, Head and Nec...
Phase PHASE1
Enrollment 22
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study is an open, multicenter, dose-escalation and cohort-expansion non-randomized phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of Lutetium \[177Lu\] BL-ARC001 in patients with locally advanced or metastatic solid tumors.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Lutetium [177Lu] BL-ARC001 — Administration by intravenous infusion for a cycle of 6 weeks.

Primary Outcomes

  • Phase Ia: Dose limiting toxicity (DLT) (Up to 42 days after the first dose)
  • Phase Ia: Maximum tolerated dose (MTD) (Up to 42 days after the first dose)
  • Phase Ib: Recommended Phase II Dose (RP2D) (Up to approximately 24 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2025-12-10
Completion: 2027-12
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 22 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.
Collaborators: Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Sa Xiao, PHD
15013238943
xiaosa@baili-pharm.com
Rui Huang
West China Hospital of Sichuan University
Rui Huang
West China Hospital of Sichuan University
Interventions
  • Drug: Lutetium [177Lu] BL-ARC001 — Administration by intravenous infusion for a cycle of 6 weeks.
Study Locations (1 sites)
West China Hospital of Sichuan University, Chengdu, Sichuan China
Eligibility Criteria
Inclusion Criteria: 1. Voluntarily sign the informed consent form and comply with the protocol requirements; 2. No gender restrictions; 3. Age: ≥18 years and ≤75 years (Phase Ia); ≥18 years (Phase Ib); 4. Expected survival time ≥3 months; 5. Histologically or cytologically confirmed locally advanced or metastatic solid tumors that have failed standard treatment; 6. Agreement to provide archived tumor tissue specimens or fresh tissue samples from primary or metastatic lesions within the past 3 years; 7. Must have at least one measurable lesion as defined by RECIST v1.1; 8. ECOG performance status score of 0 or 1; 9. Toxicity from prior antitumor therapy has recovered to ≤ Grade 1 as defined by NCI-CTCAE v5.0; 10. No severe cardiac dysfunction, left ventricular ejection fraction ≥50%; 11. Organ function levels must meet the requirements; 12. Coagulation function: International Normalized Ratio (INR) ≤1.5, and activated partial thromboplastin time (APTT) ≤1.5 × ULN; 13. Urine protein ≤2+ or ≤1000mg/24h; 14. For premenopausal women with childbearing potential, a serum pregnancy test must be performed within 7 days before starting treatment, and the result must be negative. Patients must not be breastfeeding; all enrolled patients (regardless of gender) should adopt adequate barrier contraception throughout the treatment cycle and for 6 months after treatment ends. Exclusion Criteria: 1. Use of chemotherapy, biological therapy, or immunotherapy within 4 weeks or 5 half-lives prior to the first dose; 2. History of severe heart disease; 3. Prolonged QT interval, complete left bundle branch block, or third-degree atrioventricular block; 4. Active autoimmune or inflammatory diseases; 5. Diagnosis of other malignancies within 5 years prior to the first dose; 6. Hypertension poorly controlled by two antihypertensive medications; 7. History of interstitial lung disease (ILD) requiring hormonal therapy, current ILD, or ≥ Grade 2 radiation pneumonitis; 8. Symptoms of active central nervous system metastasis; 9. History of allergy to recombinant humanized antibodies or human-mouse chimeric antibodies, or allergy to any excipient component of 177Lu-BL-ARC001; 10. Previous organ transplantation or allogeneic hematopoietic stem cell transplantation (Allo-HSCT); 11. Cumulative dose of anthracyclines \>360 mg/m² during prior (neo)adjuvant anthracycline therapy; 12. Positive human immunodeficiency virus (HIV) antibody, active tuberculosis, active hepatitis B virus infection, or active hepatitis C virus infection; 13. Active infection requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.; 14. Participation in another clinical trial within 4 weeks prior to the first dose; 15. Pregnant or lactating women; 16. Other conditions deemed by the investigator as unsuitable for participation in this clinical trial.
Conditions Locally Advanced or Metastatic Breast Ca...
Phase PHASE2
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter, open-label, phase 2 clinical study to evaluate the efficacy, safety and pharmacokinetics of YL202 in patients with locally advanced or metastatic breast cancer with TNBC, HR-positive, HER2-zero-expression or HER2-low-expression

Design

Study type: Interventional Phases: Phase2 Allocation: Non Randomized Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: YL202 should be intravenously infused — For each patient, YL202 should be intravenously infused over 60±10 min.

Primary Outcomes

  • ORR assessed according to RECIST v1.1 (By the end of trial date, approximately within 36 months)
  • Determination of the recommended dose of YL202 in the pivotal clinical study (By the end of trial date, approximately within 36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-04-23
Completion: 2028-07-29
Eligibility
Age: 18 Years – 75 Years
Sex: FEMALE
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Contact Information
Study Contact:
MediLink Study Team
+86 512 62858368
clinicaltrials@medilinkthera.com
Study Coordinator
Fudan University Shanghai Cancer Center
Interventions
  • Drug: YL202 should be intravenously infused — For each patient, YL202 should be intravenously infused over 60±10 min.
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 250117 China
Eligibility Criteria
Inclusion Criteria: 1. Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form. 2. Patients with locally advanced or metastatic disease (according to the UICC and AJCC staging system \[Version 8\]) who are not candidates for curative surgery or radiotherapy. 3. Patients who are pathologically confirmed advanced/unresectable or metastatic breast cancer with HR-negative and HER2-negative,. 4. Patients who are confirmed HR positive and HER2-Zero-expression and HER2-Low-expression. 5. Breast cancer patients who have previously failed treatments of HER2-ADC or TROP2-ADC. 6. Have at least 1 extracranial measurable lesion as a target lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 7. Have Adequate organ and bone marrow function within 7 days prior to the first dose. 8. Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug. 9. Have a expected survival ≥ 3 months. 10. Have ability and willingness to comply with protocol-specified visits and procedures. Exclusion Criteria: 1. Have prior treatment with an agent targeting HER3. 2. Have prior intolerance to treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor. 3. Have been enrolled in another clinical study concurrently unless it is an observational clinical study or in the follow-up phase of an interventional study. 4. Have insufficient washout period for prior anticancer therapy prior to first dose of the study drug. 5. Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study. 6. Have prior allogeneic bone marrow transplant or prior solid organ transplant. 7. Have received treatment with systemic steroids. 8. Have received any live vaccine within 4 weeks prior to the first dose of study drug or intend to receive a live vaccine during the study. 9. Leptomeningeal metastases or carcinomatous meningitis, spinal cord compression. 10. Brain metastases with the exceptions. 11. Have uncontrolled or clinically significant cardiovascular and cerebrovascular disease. 12. Have clinically significant concomitant pulmonary diseases. 13. Have a diagnosis of Gilbert's syndrome. 14. Have pleural effusion, abdominal effusion. 15. Have a history of gastrointestinal perforation and or fistula within 6 months prior to the first dose. 16. Have serious infection. 17. Patients with human immunodeficiency virus (HIV) infection. 18. Have active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. 19. Have any other primary malignancy within 5 years prior to the first dose of study drug. 20. Have unresolved toxicities from prior anticancer therapy. 21. Have a history of severe hypersensitivity reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies. 22. Lactating women, or women who are confirmed to be pregnant by pregnancy test within 3 days prior to the first dose.